Headquartered in London, UK, NovalGen was formed in 2019. The company is based on proprietary innovations from UCL, London UK.
NovalGen’s founder is world-renowned Professor Amit Nathwani who has a track record of developing cutting edge, transformative treatments for patients. NovalGen is a fast-moving company and has entered into strategic collaboration partnerships with key partners including St Jude for neuroblastoma, MD Anderson for acute leukemia and CMO manufacturing partnerships to leverage expertise and scale.
NovalGen has been growing into a world-class, cutting edge, Immuno-oncology company. To enable growth the company has been able to secure non-dilutive grant funding and in 2020 successfully raised series A funding from Convergys Capital, UCL Technology Fund and UCL Business.